Experiences of Postcardiotomy Assist: Pneumatic Ventricular Assist Device or Venoarterial Bypass with Percutaneous Cardiopulmonary Support

Regional Referral System for Patients with Acute Mechanical Support: Experience at The Cleveland Clinic Foundation

Regional referral networks ("hub and spoke") have been created to facilitate the transfer of patients on mechanical circulatory support. Although individual centers report good success, overall outcomes have remained poor. We investigated whether preoperative variables influenced survival and could be used to help select patients best served by referral. A retrospective chart review was conducted on all patients transferred to our institution supported on cardiac assist devices. Between January 1995 and September 2003, 39 patients were received in transfer for continued care after the implantation of a cardiac assist device. Eighty-five percent of patients had the ABIOMED BVS 5000 implanted. The most common indication was postcardiotomy shock. Sixty-four percent of patients were not candidates for heart transplantation due to medical or social contraindications. The 30-day mortality of this group was 62%. Survivors had less comorbidity and were less likely to have complex surgeries, neurologic impairment, and multisystem organ failure when presenting to our center. Devices were weaned in 30% of cases. Only six patients (15%) were successfully transplanted, and five of these patients have done well at follow-up. Based on our experience, we believe that cardiogenic shock patients benefit from a regional referral system if they have not had complex cardiac surgical procedures or developed multisystem organ failure. Furthermore, there is a survival advantage when using long-term devices because this allows possible recovery or transplantation.

Hemodynamic Effects of a New Percutaneous Circulatory Support Device in a Left Ventricular Failure Model

We have tested a new percutaneous circulatory support device in seven anesthetized calves with induced left ventricular failure. The device is based on a flexible catheter with a foldable propeller and cage at the distal end. The rotation of the propeller (1,000-15,000 rpm) is transmitted from a drive unit at the proximal end to the propeller by way of a rotating wire inside the catheter. This also contains an umbrella-like mechanism to open the pump head from the folded (diameter 4.6 mm) to the active position. The rotation of the propeller creates a pressure drop in front of the propeller and a pressure rise behind. Heart failure was induced with metoprolol and verapamil in combination with a VVI pacemaker to create a left atrial pressure greater than 20 mm Hg. A centrifugal pump was used to bypass the right ventricle and to ensure a sufficient filling of the left ventricle. After baseline recordings, the pump was run at 14,000 rpm, and the hemodynamic response was compared with the baseline. A 24 +/- 10 mm Hg pressure gradient was generated across the pump, resulting in a drop in the right carotid artery mean pressure from 80 +/- 11 to 71 +/- 13 mm Hg (p = 0.008) and a drop in the left ventricular systolic pressure from 109 +/- 17 to 100 +/- 19 mm Hg (p = 0.004). The pressure in the left atrium decreased from 25 +/- 3 to 20 +/- 5 mm Hg (p = 0.008). The mean femoral pressure increased from 78 +/- 10 to 95 +/- 20 mm Hg (p = 0.005). A moderate reduction in the right carotid flow was observed (15%, p = 0.029), whereas no significant changes were found in the coronary flow, the flow in the right femoral artery, or in the left kidney. The device showed a significant unloading of the left ventricle and an increased perfusion pressure for the lower part of the body. The moderate changes in flow were probably caused by still active autoregulation, and this needs to be tested with more pronounced circulatory failure.

Percutaneous cardiopulmonary bypass for cardiac emergencies

Percutaneous cardiopulmonary support systems (PCPS) are compact, battery-powered, portable heart-lung machines that can be implemented rapidly in any area of the hospital using thin-walled cannulae inserted via the femoral vessels. PCPS provides temporary circulatory support by actively aspirating blood from the patient's venous system using a centrifugal pump and hollow fiber membrane oxygenator for gas exchange. A review of clinical reports has delineated several indications for emergent applications, with the most frequent being cardiac arrest (CA) or cardiogenic shock (CS). Survival is more likely in patients with CS (40%) compared to CA (21%). Implementation of PCPS after unwitnessed CA or cardiopulmonary resuscitation > 30 min yields a patient survival rate of < 10%. The likelihood of patient survival after emergent PCPS is most often related to the patient undergoing a definitive anatomic surgical repair such as coronary artery bypass or pulmonary embolectomy. If the need for circulatory support extends beyond 6 h, conversion to conventional long-term extracorporeal membrane oxygenation or a ventricular assist device is recommended.

Hydrodynamic properties of a new percutaneous intra-aortic axial flow pump

Cardiac intervention, myocardial infarction, or postoperative heart failure will sometimes create a need for circulatory support. For this purpose, a new, minimally invasive intra-aortic cardiac support system with a foldable propeller has been developed. In animals, the pump has been shown to have a positive hemodynamic influence, and the present study evaluates the hydraulic properties of the pump in a bench test. The axial flow pump is a catheter system with a distal motor driven foldable propeller (0-15,000 revolutions per minute). To protect the aortic wall, filaments forming a cage surround the propeller. In the present study, tests were done with two different pumps, one with and one without the cage. Two different models were used, one for testing pressure generation and one for obtaining flow-pressure characteristics. Propellers and tubes with different diameters were studied, and pressure and flow characteristics were measured. The mathematical relationships between pressure and rotational speed, pressure, and diameter of propeller and tube were determined. There was a positive relationship between the revolutions per minute and the generated pressure, a positive relationship between the diameter of the propeller and pressure, and a negative relationship between the diameter of the tube and the generated pressure. Within the physiologic range of cardiac output, there was a small drop in pressure with increasing flow in the tubes with a small diameter. With an increasing diameter of the tube, a smaller pressure drop was seen with increasing flow. The present cardiac support system has hydraulic properties, which may be of clinical relevance for patients with left ventricular heart failure.

Percutaneous cardiopulmonary support with heparin-coated circuits in postcardiotomy cardiogenic shock. Efficacy and comparison with left heart bypass

OBJECTIVE

Percutaneous cardiopulmonary support, a simplified form of venoarterial bypass, using totally heparin-coated circuits, has recently come into clinical use. To clarify its efficacy in postcardiotomy cardiogenic shock to aid weaning from cardiopulmonary bypass, we compared results of percutaneous cardiopulmonary support with those of left heart bypass using a centrifugal pump.

METHODS

We reviewed 18 patients treated between 1991 and 1998 who could not be weaned from cardiopulmonary bypass. Nine were aided by totally heparin-coated percutaneous cardiopulmonary support (PCPS group), and 9 supported by left heart bypass using a centrifugal pump (LHB group). In both groups, activated clotting time was controlled at 150-200 seconds using minimal doses of heparin as needed.

RESULTS

Weaning and survival rates were higher in the PCPS group than in the LHB group (100% vs 55.6%, and 66.7% vs 22.2%). The PCPS group had a smaller amount of blood loss and needed a smaller amount of blood components in the immediate postoperative period. One percutaneous cardiopulmonary support patient required surgical re-exploration for postoperative bleeding (11.1%), but no clinical thromboembolic event occurred in the PCPS group. In the LHB group, 5 patients underwent surgical re-exploration for postoperative bleeding (55.6%), and 2 underwent thrombus extirpation in the left ventricle (22.2%).

CONCLUSIONS

Although this study was retrospective and historical backgrounds could have been involved, our data suggest that totally heparin-coated percutaneous cardiopulmonary support system appears more effective as an aid to weaning from cardiopulmonary bypass and in short-term circulatory support for patients in postcardiotomy cardiogenic shock.

Clinical experiences of percutaneous cardiopulmonary support: its effectiveness and limit

In recent years, several types of centrifugal pumps have been widely used as the main pumps for cardiopulmonary bypass (CPB) and postcardiotomy cardiac support. From April 1990 to March 1997, a percutaneous cardiopulmonary support (PCPS) system was used in 20 patients with an average age of 58 years (13 males and 7 females). They comprised 11 ischemic, 6 valvular, 2 aortic, and 1 congenital heart disease patients. Our PCPS system consists of a centrifugal pump (BioMedicus BP-80), an oxygenator, and a reservoir. The entire blood contacting surface, including that of the thin wall cannulas, is coated by heparin bonded materials. As a result of this new technology, this system can be used for the long term without systemic heparinization. No major critical thrombi were revealed inside the pumps or circuits. Of the 20 patients, 7 (35%) (Group 1) could be weaned from PCPS, and the remaining 13 (Group 2) could not. In Group 1 although 2 patients suffered from renal failure and pneumonia, respectively, both were discharged from our hospital. The long-term survival rate was 35%. In Group 2 cerebral vascular damage was recognized in 3 patients, renal failure in 4, multiple system organ failure in 4, bleeding in 2, arrhythmia in 1, and leg ischemia in 2. Pulse pressure was significantly elevated due to the recovery of the native heart in Group 1, 2 days after support. However, in Group 2, it did not elevate, and the left ventricular ejection fraction was less than 30%, associated with high left atrial pressure. In conclusion, this heparin coated PCPS system was very simple and easy to control. It demonstrated long-term biocompatibility and was very effective in recovering deteriorated cardiac function. Quicker application of this system can play an important role in preventing severe complications and obtaining better clinical results. If long-term support is necessary, a ventricular assist device (VAD), which is more powerful, durable, and biocompatible, has to be applied instead of PCPS.